Australian Doctor 
 News

‘Exciting’: Antiviral shows promise in reducing long COVID symptoms

US researchers say nirmatrelvir/ritonavir can reduce the risk of post-acute death and hospitalisations at 90 days
2
9 November 2022
Save
Professor Robert Booy.

A leading infectious diseases expert is cautiously optimistic that nirmatrelvir/ritonavir can reduce the risk of long-term health outcomes in patients with COVID-19. 

A pre-print study involving some 56,000 US veterans infected with SARS-CoV-2 found the antiviral combination cuts the risk of post-acute death and hospitalisations by 48% and 30%, respectively, versus controls. 

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .